In August 2010, Mexican President Felipe Calderon declared that he would support a national debate on the issue of legalisation, reversing his previous stance on the subject. However, he underscored that he did not favour legalisation, particularly since the US and the international community maintained their prohibitionist approach. This IDPC Briefing Paper offers background information on the cannabis political debate in Mexico.
The Expert Dialogue took place in the Miramar Palace in San Sebastian and was hosted by the municipal authorities of the city. Dialogue focused on examining some regulation models currently being implemented.
The Netherlands has long been considered a leader of progressive drug policy, but it is increasingly being left behind by policy innovations outside Europe. Nonetheless Dutch cities are leading the way towards more progressive and locally adapted cannabis policies. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of Dutch cannabis policy today, and the possibilities for its future.
Uruguay’s senate voted today (10 December) to approve the world’s first national legal framework regulating the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes.
Cannabis was condemned by the 1961 Single Convention on Narcotic Drugs as a psychoactive drug with “particularly dangerous properties” and hardly any therapeutic value. Ever since, an increasing number of countries have shown discomfort with the treaty regime’s strictures through soft defections, stretching its legal flexibility to sometimes questionable limits.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
Stephen Rolles argues that we need to end the criminalisation of drugs and set up regulatory models that will control drug markets and reduce the harms caused by current policy. Non-medical drug markets can remain in the hands of unregulated criminal profiteers or they can be controlled and regulated by appropriate government authorities.
Economists have been among the leading critics of current drug policies, but this criticism does not mean they have reached a consensus about specific reforms. Although drug-policy researchers and economists in general seem opposed to prohibition, they are timid in their advocacy of decriminalization and even less supportive of legalization.
Ernestien Jensema (1971) is a social anthropologist who has been working as a researcher and project coordinator with the Drugs & Democracy Programme of TNI since 2008. She focuses on issues related to the UN drug control system and the Drugs and Democracy Programme’s Asia project....
In order to better understand the situation around, and possibilities for, local and regional cannabis regulation, a series of six country reports were developed. The country reports provide detailed information about the state of cannabis policy, and the possibilities for change, within each country. This briefing identifies some of the key findings and implications for policy makers and advocates from this research.
The application of regulatory theory to the problem of illicit drugs has generally been thought about only in terms of ‘command and control’. The international treaties governing global illicit drug control and the use of law enforcement to dissuade and punish offenders have been primary strategies. In this paper the application of other aspects of regulatory theory to illicit drugs – primarily self-regulation and market regulation – are explored. There has been an overreliance on strategies from the top of the regulatory pyramid.
The CATO report estimates that legalizing drugs would save roughly $41.3 billion per year in government expenditure on enforcement of prohibition. Of these savings, $25.7 billion would accrue to state and local governments, while $15.6 billion would accrue to the federal government. Approximately $8.7 billion of the savings would result from legalization of marijuana and $32.6 billion from legalization of other drugs.
Despite efforts by governments in Latin America, illicit drugs continue to provide one of the largest incomes for criminal organizations, enabling them to penetrate and corrupt political and social institutions.
This paper starts from the premise that, when a new psychoactive substance appears on the licit/illicit market in a country in Europe, legislators need to choose whether to bring it under control of the drug laws, and for public health reasons they may need to do so quickly. A comparative study of the systems and procedures finds that there are a variety of control methods available in the different countries, including the analogue and generic systems, as well as temporary emergency and rapid permanent scheduling procedures.
Khat has been consumed for thousands of years in the highlands of Eastern Africa and Southern Arabia.Strict bans on khat introduced in Europe ostensibly for the protection of immigrant communities have had severe unintended negative consequences.
Benedikt Fischer, Victoria Jeffries, Wayne Hall, Robin Room, Elliot Goldner, Jürgen Rehm
01 September 2011
More than one in ten adults – and about one in three young adults – report past year cannabis use in Canada. While cannabis use is associated with a variety of health risks, current policy prohibits all use, rather than adopting a public health approach focusing on interventions to address specific risks and harms as do policies for alcohol. The objective of this paper was to develop ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) based on research evidence on the adverse health effects of cannabis and factors that appear to modify the risk of these harms.
Uruguay’s senate voted today (10 December) to approve the world’s first national legal framework regulating the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes. The historical vote is expected to inspire and spread cannabis reform initiatives around the world and to have a major impact on upcoming UN-level drug policy evaluations.
How does national legislation in different EU member states compare and how effective is the adding of new psychoactive substances (NPS) to the existing schedules of drug laws versus legislative experimentation designing new schedules or applying controls under medicines or consumer protection regulations?